TRIENTINE WAYMADE (Waymade Australia Pty Limited)

Product name

TRIENTINE WAYMADE

Date registered

11 January 2021

Evaluation commenced

30 January 2020

Decision date

7 January 2021

Approval time

188 (255 working days)

Active ingredients

trientine dihydrochloride

Registration type

NCE/NBE

Indication

TRIENTINE WAYMADE (capsule) is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Registration process

Orphan drug

Sponsors receive a fee waiver to help bring medicines for a small population to market.